Cadonilimab

Cadonilimab is a PD-1/CTLA-4 bispecific monoclonal antibody^[1]^[2] developed to treat a variety of solid cancer types. In June 2022 it was approved in China "for use in patients with relapsed or metastatic cervical cancer (r/mCC) who have progressed on or after platinum-based chemotherapy".^[3]

References[edit]

^ Pang, Xinghua; Huang, Zhaoliang; Zhong, Tingting; Zhang, Peng; Wang, Zhongmin Maxwell; Xia, Michelle; Li, Baiyong (2023). "Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity". mAbs. 15 (1): 2180794. doi:10.1080/19420862.2023.2180794. ISSN 1942-0862. PMC 10012886. PMID 36872527.
^ Gao, Xiangyu; Xu, Nong; Li, Ziyu; Shen, Lin; Ji, Ke; Zheng, Zhong; Liu, Dan; Lou, Hanmei; Bai, Li; Liu, Tianshu; Li, Yunxia; Li, Yuzhi; Fan, Qingxia; Feng, Mei; Zhong, Haijun; Huang, Yi; Lou, Ge; Wang, Jing; Lin, Xiaoyan; Chen, Ye; An, Ruifang; Li, Changzheng; Zhou, Qi; Huang, Xin; Guo, Zengqing; Wang, Shubin; Li, Guiling; Fei, Junwei; Zhu, Lijing; Zhu, Hong; Li, Xiumin; Li, Fenghu; Liao, Sihai; Min, Qinghua; Tang, Lei; Shan, Fei; Gong, Jifang; Gao, Yunong; Zhou, Jun; Lu, Zhihao; Li, Xiaofan; Li, Jianjie; Ren, Hui; Liu, Xiaohong; Yang, Hongxia; Li, Wenting; Song, Weifeng; Wang, Zhongmin Maxwell; Li, Baiyong; Xia, Michelle; Wu, Xiaohua; Ji, Jiafu (October 2023). "Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial". The Lancet Oncology. 24 (10): 1134–1146. doi:10.1016/S1470-2045(23)00411-4. PMID 37797632. S2CID 263641919.
^ Keam, Susan J. (August 2022). "Cadonilimab: First Approval". Drugs. 82 (12): 1333–1339. doi:10.1007/s40265-022-01761-9. PMID 35986837. S2CID 251672945.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.